We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

A recent study published in Quaternary Research describes the discovery and identification of possible aardvark tracks and ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Morgan Stanley started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued an overweight ...

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...

Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Aardvark Therapeutics in a report released on Monday, March 10th. Cantor Fitzgerald analyst J ...

Morgan Stanley initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $29 price target The firm believes the Phase 2 ...

Aardvark Therapeutics has raised $94.2m in an initial public offering (IPO) to support the development of its hunger-suppressing drug ARD-101 for the rare disease Prader-Willi syndrome.

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations. The company’s 5.9 million shares will be offered at $16 apiece ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following the company's $94M initial public offering. Aardvark (NASDAQ:AARD) shares opened at $15.18 after ...

In this article, we are going to take a look at where Aardvark Therapeutics, Inc. (NASDAQ:AARD) stands against other stocks with at least $10 million in insider spending recently. Since Donald ...